Introduction
The p53 gene is mutated in more than 50% of human cancers (Prokocimer and Rotter, 1994; Imamura et al., 1994) , and germline p53 mutations render humans (Malkin et al., 1990) or gene-targeted mice (Donehower et al., 1992) cancer-prone. p53 encodes a 393 amino acid phosphoprotein with an Nterminal transcriptional activation domain, a central DNA-binding domain, and a C-terminal tetramerization and regulatory domain (Gottlieb and Oren, 1996; Ko and Prives, 1996; Vogelstein and Kinzler, 1994; Lane, 1993) . The main biological functions of this prototypic tumor suppressor are control of cell proliferation and induction of apoptosis in response to DNA damage (Vogelstein and Kinzler, 1992; Canman et al., 1994) , oncogene expression (White et al., 1994; White, 1995) , hypoxia (Graeber et al., 1996) , and other stimuli (Linke et al., 1996; Jayaraman et al., 1997) . p53 acts either through transcriptional activation of at least six genes, i.e., those encoding p21/WAF1/Cip1, MDM2, GADD45, Cyclin G, Bax and IGF-BP3, or via less well understood transcriptional activation-independent mechanisms. Cell cycle regulation has been associated with transcriptional induction of the cyclin-dependent kinase inhibitor p21 (Dulic et al., 1994; El-Deiry et al., 1993) and perhaps other genes, like that encoding the PCNA-binding GADD45 protein (Smith et al., 1994) .
The molecular pathway leading to p53-mediated apoptosis is less well understood. Both transcriptional activation-dependent and -independent mechanisms have been implicated. Which pathway prevails may depend upon the cell type or experimental situation (Haupt and Oren, 1996; Levine, 1997) . Concerning a possible role of p53-induced genes, p21 has been studied in great detail, but with controversial results. The majority of studies, including work with p21-de®cient mice, suggest that p21 plays no role in (Brugarolas et al., 1995; Deng et al., 1995) , or even protects from (Gorospe et al., 1997) , p53-induced cell death, while other studies propose a causal involvement of p21 in certain experimental systems (Gorospe and Holbrook, 1996) . More likely candidates for p53-induced apoptosis genes are those encoding the proapoptotic Bcl-2 family member Bax (Miyashita and Reed, 1995; Yin et al., 1997; McCurrach et al., 1997) , the insulin-like growth factor-binding protein 3 (IGF-BP3) (Buckbinder et al., 1995) , and the Apo1/Fas/ CD95 membrane receptor (Owen-Schaub et al., 1995) , although p53 response elements in the latter gene have not yet been demonstrated (Levine, 1997) . Transcriptional activation-independent mechanisms for p53-mediated apoptosis have been based upon the failure of macromolecule biosynthesis inhibitors to prevent p53-dependent apoptosis (Caelles et al., 1994) and upon the induction of cell death with transactivationcompromised p53 mutants (Haupt et al., 1995) . The molecular basis underlying transcriptional activationindependent p53 apoptosis is not known, but may include transcriptional repression of anti-apoptotic genes, such as bcl-2 (Haldar et al., 1994; Miyashita et al., 1994) .
Thus, although the ®rst components of the p53-triggered death pathway are emerging, its complete composition is far from being understood. With respect to the eector phase, activation of interleukin-1b-converting enzyme (ICE) ± like proteases, now referred to as caspases (Alnemri et al., 1996) , was involved in the terminal pathway in essentially all apoptosis systems investigated (Henkart, 1996) . These enzymes may be activated in a cascade-like fashion and speci®cally cleave important cellular proteins which ultimately leads to the common morphologic characteristics of apoptosis (Vaux et al., 1994; White, 1996; Fraser and Evan, 1996) . At present, at least ten caspases have been described (Kumar, 1995; Alnemri et al., 1996) . Current evidence suggests that, although all apoptosis forms may involve caspase activation, important dierences could exist in the particular caspases activated in each. For instance, the caspases in glucocorticoid-or ceramide-induced apoptosis are dierent from those activated during cell death elicited by antibodies to the Apo1/Fas/CD95 membrane protein (Geley et al., 1997a,b) . The caspases activated in, and required for, p53-induced apoptosis are part of this study and will be dealt with in the Discussion.
In the present study, we investigated the widely used human acute lymphoblastic T-cell leukemia model CCRF-CEM (Norman and Thompson, 1977) , which is a compound heterozygote for the p53 mutations R175H and R248Q (Cheng and Haas, 1990) . We ®rst showed that CCRF-CEM cells underwent apoptosis upon reconstitution with functional p53 (as a temperature-sensitive mutant), suggesting that the endogenous p53 mutations may contribute to the malignant phenotype by allowing escape from apoptosis. Since p53-induced cell death has not been studied in great detail in these or other human T-cell leukemia cells, we investigated various characteristics of this form of apoptosis, including involvement of caspases, dependence on macromolecule biosynthesis, and in¯uence of loss of wild-type p53 on sensitivity to chemotherapy.
Results
Introduction of p53 induces apoptosis in p53-de®cient CEM cells CEM cells are compound heterozygotes for the mutant p53 alleles R175H and R248Q (Cheng and Haas, 1990) . To assess whether these mutations contribute to the malignant phenotype, we stably introduced a temperature-sensitive p53 mutant into CEM-C7H2 cells. As shown in Figure 1 , corresponding cell lines expressed signi®cant levels of the transfected mouse p53. Upon shift to the permissive temperature, the transfected p53 became activated, as shown by induction of transcripts from typical p53-regulated genes, such as p21 (Figure 2a ), bax (Figure 2b ), and mdm-2 (not shown). Consequent to p53 activation, p53ts-transfected CEM-C7H2 sublines underwent extensive apoptosis after 24 ± 36 h, as shown by three dierent methods for detection of apoptosis (TUNEL, propidium iodide staining, scanning microscopy; Figure 3a and b). These data indicated that all necessary components for p53-mediated apoptosis are functional and present in CEM derivatives, and suggested that mutational p53 inactivation may contribute to the malignant phenotype of these leukemic cells by interfering with their ability to mount p53-dependent apoptosis. , and overlaps of both scans (E, F). The apoptotic cell reveals a green stained nucleus after 3'OH DNA labeling by the TUNEL technique; shrinkage and`membrane blebbing' are visible in the transmission scan (original magni®cation 636oil; 806zoom) p53-induced apoptosis in human leukemia S Geley et al through, caspase activation, we investigated expression of the nuclear enzyme PARP, a typical target of such proteases. As shown in Figure 4 , PARP cleavage into fragments typical for the action of caspases preceded p53-induced apoptosis in CEM cell lines expressing p53ts. To test whether caspases are essential for p53-induced cell death, we treated p53ts-expressing and parental CEM-C7H2 cells with peptide inhibitors with dierent caspase speci®cities. The tripeptide inhibitor zVAD, which has a broad speci®city for various caspases (Jacobsen et al., 1996; Slee et al., 1996) and the tetrapeptide DEVD, which inhibits`eector caspases' like CPP32/caspase-3 (Nicholson et al., 1995) , almost completely blocked apoptosis induction at 328C (Figure 5a ). In contrast, the predominantly ICE/caspase-1 and FLICE/caspase-8-speci®c tetrapeptide YVAD did not signi®cantly block p53-induced cell death (Figure 5a ), although identical concentrations of this inhibitor abrogated Apo-1/Fas/CD95-induced apoptosis ( Figure 5b ). This form of cell death is known to critically depend upon caspases 1 and 8 (Kuida et al., 1995; Boldin et al., 1996; Muzio et al., 1996) . Thus, p53-mediated apoptosis depended upon some caspases but was largely independent of others, namely those critical for Apo-1/Fas/CD95-induced cell death.
p53-induced apoptosis depends upon macromolecule biosynthesis
The question of whether p53 induces apoptosis via its transactivational or transrepressional activities, or through transcription-independent interactions or both, has not been de®nitively determined and may depend on the cell type, state of dierentiation or other factors. To further address this issue in leukemia cells, we treated p53ts-transfected and parental CEM-C7H2 cells with cycloheximide and actinomycin D, which inhibit translation and transcription, respectively. Even at relatively low concentrations of both agents, treatment of C7H2 cells at 378C resulted in apoptosis (not shown), but this eect was markedly delayed at 328C, thereby allowing analysis of the eect of macromolecule biosynthesis inhibition on p53-induced apoptosis. Exposure of p53ts lines to 100 nM actinomycin D 2 h prior to and during temperature shift markedly reduced p53-induced apoptosis. A similar treatment with 10 mM cycloheximide also resulted in inhibition of p53-dependent apoptosis, suggesting that induction of p53-regulated proteins might be involved in p53-induced apoptosis ( Figure 6 ). p53 increases sensitivity to doxorubicin but not to vincristine p53 appears to be involved in apoptosis induced by certain chemotherapeutic drugs and the presence of p53 mutations has been correlated with relative resistance to such agents in some (Perego et al., 1996; Anthoney et al., 1996) , but not other, systems (Thomas et al., 1996) . We investigated whether functional p53 might alter the response of CEM leukemic cells to chemotherapy, particularly to vincristine, a representative of antimitotic tubulin-active compounds, and to the topoisomerase inhibitor doxorubicin, a DNAdamaging agent. To this end, we treated parental 
C7H2 p53ts
Figure 4 PARP is cleaved during p53-induced apoptosis. Shown is a Western analysis of parental CEM-C7H2 line (C7H2) and three CEM-C7H2 subclones stably transfected with mouse p53ts (4G5, 3E12, 3H3) cultured at either 378C or 328C for 14 h. Whole cell extracts were separated by PAGE, transferred to ®lters, and incubated with a speci®c goat antiserum to PARP. An 85 kDa PARP-fragment, typical for cleavage by caspases, is produced after shifting the p53ts-transfected subclones to the permissive temperature (328C), but not in parental CEM-C7H2 at either 378C or 328C, or in p53ts-transfected subclones at 378C a b Figure 5 p53-induced apoptosis is prevented by zVAD and DEVD, but only marginally by YVAD. Parental CEM-C7H2 and p53-transfected CEM-C7H2 sublines 4G5, 3E12 and 3H3 were cultured at 328C for 24 h in the absence (`Medium', black bars) or presence of 50 or 100 mM zVAD (open bars), DEVD (crosshatched bars), or 100 mM YVAD (stippled bars), and subjected to apoptosis determination by PI staining and FACS analysis. Culture at the permissive temperature of 328C caused signi®cant apoptosis in the p53ts-transfected subclones that was almost completely prevented by both concentrations of zVAD and DEVD (the bars represent combined data from 50 and 100 mM), but only marginally by 100 mM YVAD. The same concentration of YVAD, however, completely prevented apoptosis induced by an antibody to Apo1/Fas/CD95 in C7H2 and p53ts-transfected subclones, as exempli®ed with 3H3 cells in (b). The cells were treated with anti-Apo1/Fas/CD95 antibody CH11 for 6 h (open bars) and 12 h (black bars) either in the absence or presence of 100 mM YVAD and subjected to apoptosis determination as above p53-induced apoptosis in human leukemia S Geley et al C7H2 and its p53ts-transfected subclones with doxorubicin or vincristine in parallel at 378C, the temperature at which the transgenic p53ts is inactive, and at 328C, where p53ts is functional. As shown in Figure 7a , after 18 h exposure to up to 400 ng/ml doxorubicin at 378C, no signi®cant apoptosis was induced in any of the four cell lines. However, when the cells were cultured at 328C, the sublines expressing functional p53 (but not the parental C7H2 line) underwent signi®cant apoptosis that clearly exceeded that induced by the activated p53 in the absence of doxorubicin (medium control in Figure 7a ). In contrast, no such cooperative eect was observed when the cells were exposed to the tubulin-active compound vincristine, although the chemotherapeutic drug had some apoptosis-inducing eect in the absence of functional p53, i.e., at 378C.
Discussion

p53 mutations in CCRF-CEM cells and human leukemia
Although p53 mutations in primary leukemia are relatively rare, up to 70% of leukemia cells recovered after relapse contain p53 gene alterations, suggesting a critical role for p53 in leukemia progression and resistance to chemotherapy (Imamura et al., 1994) . CCRF-CEM cells express p53 alleles that carry one of two missense mutations, R175H or R248Q (Cheng and Haas, 1990 ) that disrupt the tertiary structure of p53 (175H) (Prives, 1994; Cho et al., 1994; Vogelstein and Kinzler, 1994) or compromise DNA-binding and subsequent gene transactivation (248Q) (Rolley et al., 1995) . Transcriptional activation-independent functions of p53 may be preserved in the latter mutant, and transcomplementation between the two mutants may recover functions not present in the individual mutants. Hence, it is unclear whether CCRF-CEM cells are de®cient in all, or perhaps only some, p53 functions. Park et al. (1994) reported considerable transactivating ability of p53 on a transfected reporter construct in CEM cells, suggesting residual and constitutive activity of the mutant p53 in these cells. Our data disagree with this conclusion derived from these episomal transactivation assays: none of the endogenous p53-responsive genes investigated (p21/ WAF1, mdm-2, bax) was detectably expressed in CEM-C7H2 cells even though they could be induced by introduction of exogenous functional p53. Moreover, endogenous CEM p53 is apparently incapable of driving the cells into apoptosis despite the fact that all p53-dependent death pathway components are functionally present, as shown by the ability of transfected p53 to induce apoptosis without further activating stimulus. Taken together, our data suggest that the above mutations rendered CEM cells p53-de®cient, at least with respect to p53-mediated transactivation of some genes and apoptosis induction, and that this de®ciency may contribute to the malignant phenotype of this leukemia line.
Caspases in p53-dependent and -independent apoptosis
Caspase activation has been associated with apoptosis in a large number of systems and has become a hallmark of apoptosis. However, which of the increasing number of caspases participate in a given form of apoptosis or cell type and their precise order of Subsequently, all samples were subjected to apoptosis determination by PI staining and FACS analysis. Treatment with up to 400 ng/ml doxorubicin at 378C did not induce signi®cant apoptosis (a). However, when incubated at 328C, the p53ts-transfected cell lines showed apoptosis levels markedly higher than those in the presence of medium alone. In contrast, vincristine treatment did not reveal such a cooperative eect with p53 (b). Shown are means+standard deviation from three experiments (a) and means+range from two experiments (b). Similar results were obtained after 15 h and 21 h (not shown)
p53-induced apoptosis in human leukemia S Geley et al activation is not well understood. Our observations of PARP cleavage during p53-induced apoptosis and inhibition of cell death by DEVD (and zVAD) suggested involvement of typical`eector caspases' like CPP32/caspase-3 or Mch3/caspase-7 that specifically cleave this target and are inhibited by DEVD (Lazebnik et al., 1994; Fernandes-Alnemri et al., 1995) . This is in agreement with, and extends, recent reports of p53ts-induced cell death in M1 myeloid leukemia cells showing partial inhibition by zVAD (Lotem and Sachs, 1996) and activation of CPP32/caspase-3 or Mch3/caspase-7 (Chandler et al., 1997) . The failure to signi®cantly inhibit p53-mediated apoptosis by YVAD (Figure 5a ), a tetrapeptide inhibitor with preferential speci®city for ICE/caspase-1 and presumably FLICE/ caspase 8 (Lazebnik et al., 1994; Srinivasula et al., 1996) , suggested that these enzymes may not be essential in this phenomenon. This clearly separated p53-dependent apoptosis from at least one form of p53-independent cell death, i.e., Apo1/Fas/CD95-induced apoptosis. The latter could be blocked by YVAD in CEM cells (Figure 5b ), an observation that has also been made in Jurkat cells, another human T-ALL line (Armstrong et al., 1996; Juo et al., 1997) . However, other p53-independent cell death forms, like GC-induced or ceramide-induced apoptosis, behaved similar on a mechanistic level, i.e., they were inhibited by zVAD but not by YVAD or crmA (Geley et al., 1997a,b; Hartmann et al., in preparation) .
Macromolecule biosynthesis requirement and genes involved in p53-induced apoptosis
As discussed in the Introduction, p53 may signal cell death through sequence-speci®c transcriptional activation-dependent and -independent pathways. Our ®nding of inhibition of p53-mediated apoptosis by both actinomycin D and cycloheximide supports a critical role of activation of gene transcription (and subsequent translation) in p53-induced apoptosis in this human Tcell leukemia system. Which p53-induced target genes might be induced in, and perhaps be critical for, p53-mediated cell death has also been addressed. Thus, mdm-2 steady state mRNA levels increased upon temperature shift (data not shown), but this probably re¯ected negative feedback regulation of p53 rather than a component of the apoptotic response. Similarly p21/WAF1 mRNA appeared induced during p53-mediated apoptosis (Figure 2a) , suggesting that contrary to other systems (Gorospe et al., 1997) , p21 does not play a dominant protective role in CEM cells. However, whether p21 induction in CEM cells is a causal component of the death pathway, as shown in MCF-7 cells (Gorospe and Holbrook, 1996) , or a phenomenon unrelated to p53-mediated apoptosis, as suggested in many other systems (Brugarolas et al., 1995; Deng et al., 1995) , remains to be determined. Of the three most likely candidates for p53-induced apoptosis genes (Apo-1/Fas/CD95, IGF-BP3, bax), a central role of Apo1/Fas/CD95 induction was ruled out by our experiments with peptide caspase inhibitors: YVAD completely prevented Apo1/Fas/CD95-induced apoptosis, but had little eect on p53-mediated cell death (Figure 5a and b) . Thus, contrary to a recent suggestion (Owen-Schaub et al., 1995), induction of Apo1/Fas/CD95 by p53 may not play a signi®cant role in p53-mediated apoptosis, at least in this human leukemia model. This conclusion is in agreement with data from ICE-de®cient mice showing compromised Apo1/Fas/CD95-induced cell death, but an apparently undisturbed p53-dependent apoptotic response (Kuida et al., 1995) . IGF-BP3 (Buckbinder et al., 1995) is implicated primarily in growth factor withdrawalassociated apoptosis and, since p53 induced cell death in the presence of sucient growth factors, is not a likely candidate in our system. Bax, however, whose critical role in p53-mediated brain cell apoptosis has recently been ®rmly established (Yin et al., 1997) , and whose expression was increased during p53-mediated CEM cell apoptosis (Figure 2b ), appears to be the most promising candidate for the primary p53 response gene in this cell death pathway.
p53 and sensitivity to chemotherapy
The last section of this study addressed the in¯uence of p53 on chemotherapy of CEM leukemia cells, and provided evidence that functional p53 increased sensitivity to the topoisomerase inhibitor doxorubicin, a representative DNA-damaging drug, but not to the tubulin-active compound, vincristine. This ®nding is in good agreement with a large study by the National Cancer Institute that linked topoisomerase inhibitor sensitivity to cell lines with intact p53, while toxicity of several tubulin-active agents, including vincristine, was unaected by the p53 status (Weinstein et al., 1997) . Interestingly, while doxorubicin treatment for up to about 18 h failed to induce signi®cant apoptosis at 378C (Figure 7a ), the drug did cause marked apoptosis when the cells were cultured for 24 h or longer at 378C (data not shown). Thus, unlike vincristine, doxorubicin can trigger cell death via a p53-dependent and, although less eciently, -independent pathway. Taken together, the evaluation of the p53 status of a given patient's leukemia cells might be useful in the selection of chemotherapeutic agents.
Materials and methods
Cell culture and reagents
All cell lines were grown in 5% CO 2 , saturated humidity, at 378C in RPMI 1640 supplemented with 5 ± 10% bovine calf serum (HyClone, Logan, UT), 100 U/ml penicillin, 100 mg/ ml streptomycin and 2 mM L-glutamine. To activate the temperature-sensitive p53 mutant, p53ts lines were cultured as above, but at 328C. Acetyl-Tyr-Val-Ala-Asp chloromethylketone (YVAD, 10 mM stock in methanol) was obtained from Calbiochem, San Diego, CA, benzyloxycarbonyl -Val -Ala -Asp¯uoromethylketone (zVAD, 10 mM stock in DMSO) and benzyloxycarbonyl-Asp -Glu -ValAsp.¯uoromethylketone (DEVD, 10 mM stock in DMSO) from Enzyme System Products, Dublin, CA. The monoclonal IgM anti-Apo1/Fas/CD95 antibody CH11 (0.5 mg/ ml) was obtained from Kamiya, Thousand Oaks, CA. Doxorubicin (2 mg/ml in physiologic saline) and vincristine (Oncovin, 2 mM in saline) were from Ebewe (Unterach, Austria), all other reagents were from Sigma (Vienna, Austria), unless indicated otherwise.
Stable transfections
Logarithmically growing CEM-C7H2 cells (Strasser-Wozak et al., 1995) were washed in phosphate buered saline (PBS:
136.89 mM NaCl, 10.14 mM Na 2 HPO 4 , 2.68 mM KCl and 1.76 mM KH 2 PO 4 , pH 7.4), pelleted at 300 g and resuspended at a density of 1610 7 cells/400 ml PBS. Cells were mixed with 20 mg PvuI-linearized pLTRp53V135 (YonishRouach et al., 1991) together with either 20 mg pRC/CMV (InVitrogen, Leek, The Netherlands) or 10 mg BamHIlinearized p3'SS (Stratagene, La Jolla, CA), incubated for 10 min on ice, and electroporated (Biorad Lab., Vienna, Austria) at 960 mF and 300 ± 350 V. After electroporation, cells were placed on ice for another 10 min, diluted in 20 ml growth medium and seeded on 96-well¯at bottom plates. Selection of stably transfected cells was initiated 48 h after electroporation using either 1 mg/ml G418 (bioactivity 70%, GIBCO BRL Life Technologies, Eggenstein, Germany) for pRC/CMV cotransfected cells or 0.25 mg/ml hygromycin B (Boehringer Mannheim, Vienna, Austria) for p3'SS cotransfected cells.
Determination of apoptosis
For detection and quanti®cation of apoptosis, nuclear staining with propidium iodide in concert with forward/ sideward scatter analysis (Nicoletti et al., 1991) was used and, in some instances, con®rmed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) of DNA fragmentation sites (Gavrieli et al., 1992) and microscopic analysis. TUNEL was performed as detailed by . Brie¯y, 1610 6 cells were ®xed in 200 ml 2% paraformaldehyde for 30 min at room temperature, washed in phosphate-buered saline (PBS, pH 7.2)/1% bovine serum albumin, permeabilized with 100 ml 0.1% Triton X-100/0.1% sodium citrate for 2 min on ice, washed twice and then incubated for in situ endlabeling with 0.03 nmol FITC-12-dUTP (BoehringerMannheim, Germany), 3 nmol dATP, 2 ml 25 mM CoCl 2 , 25 units terminal deoxynucleotidyl transferase in a ®nal volume of 50 ml 30 mM TRIS pH 7.2/140 mM sodium cacodylate for 1 h at 378C. The reaction was stopped by 2 ml 0.5 M EDTA and the cells were washed twice in PBS. Samples were quanti®ed on a FACScan (Becton Dickinson, San Jose, CA) using an argon laser (488 nm). Morphologic studies were performed with a Zeiss LSM 10 confocal laser scanning microscope (Zeiss, Oberkochen, Germany).
For analysis of nuclear staining with propidium iodide (Nicoletti et al., 1991) , 1 ml of cells was centrifuged (5 min, 378C, 350 g), the supernatant discarded and the pellet stained with 750 ml freshly prepared propidium iodide (50 mg/ml in 0.1% Triton X-100/0.1% sodium citrate). Subsequently, the nuclei were subjected to apoptosis analysis in a FACScan (Becton Dickinson, San Jose, CA) using forward/sideward scatter and¯uorescence intensity as parameters. Cell debris and small particles were excluded from further analyses based on forward/sideward scatter criteria as described . Using these parameters, apoptotic nuclei appear smaller (lower forward scatter values) and more granulated (higher sideward scatter values) than living cells. Based on propidium iodide staining, nuclei in the sub-G1 marker window were considered to represent apoptotic cells.
Immunoblot analyses
Detection of PARP cleavage has been detailed (Geley et al., 1997a) . Brie¯y, whole cell lysates were separated on denaturing polyacrylamide gels, transferred to nitrocellulose and incubated with polyclonal anity-puri®ed goat antibodies against human PARP followed by horseradish peroxidase-labeled secondary antibodies. The horseradish peroxidase activity was detected by the chemiluminescent substrate SuperSignal TM (Pierce, Rockford, USA) and subsequent exposure on a Kodak Biomax MR ®lm (Kodak, Vienna, Austria).
For p53 Western blot analyses, cells were washed twice in cold PBS, lysed in 1% NP40/10 mM sodium¯uoride with fresh protease inhibitors (10 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride) for 30 min on ice, and non soluble fraction removed by centrifugation (16 000 g for 20 min). The samples were solubilized in sample buer (50 mM TRIS.HCl, pH 6.8; 10% glycerine; 2% SDS; 0.1% bromphenol blue), separated on 4.5 ± 30% gradient SDS-polyacrylamide gels along with a high molecular weight-SDS calibration marker containing the 53 kD protein glutamic dehydrogenase (Pharmacia Biotech, Uppsala, Sweden) and electrotransferred to nitrocellulose. The memebranes were blocked for 1 h with 1% BSA/PBS at room temperature and incubated with a mouse monoclonal antibody against mouse p53 (PAb122, kindly provided by Dr C Larcher, Innsbruck) (Gurney et al., 1980) for 1 h at room temperature. After washing the membranes, the speci®cally-bound antibody was detected using biotinylated anti-mouse IgG antibody (Southern Biotechnology Association, Birmingham, AL; 1 : 2000 in 1% BSA/PBS) and horseradish peroxidase-streptavidin (DAKO, Glostrup, Denmark; 1 : 3000 in 1% BSA/PBS) each for 1 h at room temperature. After three washings in PBS/Tween (5 min each), the membranes were developed with 0.05% Chloronaphtol (Sigma, Vienna, Austria) in 50 mM TRIS.HCl (pH 7.4)/0.012% H 2 O 2 .
Northern analysis
Northern analyses were performed as previously described (Geley et al., 1996) . Brie¯y, total RNA was extracted by a single step extraction procedure, separated on formaldehyde-agarose gels, blotted onto nitrocellulose membranes and baked at 808C. The ®lters were prehybridized to block nonspeci®c binding and hybridized to heat-denatured 32 Plabeled mouse bax, and human p21, mdm2, or a-tubulin cDNA probes, respectively (kindly provided by Drs S Korsmeyer, S Elledge, K Roemer and A Helmberg). The washed blots were exposed to an Agfa Curix X-ray ®lm with an amplifying screen at 7908C for 3 ± 24 h. Between hybridizations, blots were stripped with 0.1% SDS at 808C.
